Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib and Cobimetinib in BRAF V600E Mutated Papillary Craniopharyngiomas
NCT03224767Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, cobimetinib in Papillary craniopharyngioma (pCP), sponsored by Cancer and Leukemia Group B. Started Jan 2018; status: active, not recruiting.
02
Drugs
vemurafenibcobimetinib
03
Conditions
Papillary craniopharyngioma (pCP)
Beyond the preview
Go deeper on NCT03224767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224767.